04:54 AM EST, 11/08/2024 (MT Newswires) -- Amgen ( AMGN ) said late Thursday that its drug, Tezspire, which it co-developed with AstraZeneca ( AZN ) to treat patients with chronic rhinosinusitis with nasal polyps, met primary goals in a phase 3 study.

The study showed a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion in patients treated with Tezspire compared to placebo.

The drugmaker said its drug also met secondary endpoints.

Tezspire is currently approved for the treatment of severe asthma in the US, the EU, Japan, and more than 50 other countries worldwide.

Price: 325.00, Change: +5.71, Percent Change: +1.79